Trial Profile
A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel (EU-authorized) in patients with moderate to severe, active rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms EQUIRA
- Sponsors HEXAL; Sandoz
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 15 Jun 2018 Results presented in a Sandoz Media Release.